600479.SH
千金药业
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 9.80
+0.41%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 3.6B | 3.6B | 3.6B | 3.8B | 4.0B |
| Cost of Revenue | 1.8B | 1.9B | 1.9B | 2.0B | 2.3B |
| Gross Profit | 1.8B | 1.8B | 1.7B | 1.8B | 1.7B |
| Operating Expenses | |||||
| R&D Expense | 163.1M | 185.6M | 220.2M | 149.1M | 113.8M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 309.2M | 306.1M | 290.2M | 263.6M | 264.8M |
| Selling & Marketing Expense | 890.3M | 875.0M | 849.5M | 904.3M | 911.6M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 1.4B | 1.4B | 1.4B | 1.3B | 1.3B |
| Cost and Expenses | 3.2B | 3.2B | 3.3B | 3.4B | 3.6B |
| Operating Income (EBIT) | 454.6M | 437.3M | 332.1M | 461.9M | 444.2M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 452.2M | 435.1M | 335.3M | 460.4M | 445.8M |
| Income Tax Expense | 64.6M | 59.4M | 32.7M | 65.4M | 58.7M |
| Bottom Line | |||||
| Net Income | 308.1M | 286.3M | 230.8M | 320.4M | 302.5M |
| Earnings from Cont. Ops | 387.5M | 375.7M | 302.6M | 395.0M | 387.1M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 308.1M | 286.3M | 230.8M | 320.4M | 302.5M |
| Per Share | |||||
| Basic EPS | CN¥0.70 | CN¥0.66 | CN¥0.56 | CN¥0.76 | CN¥0.71 |
| Diluted EPS | CN¥0.70 | CN¥0.66 | CN¥0.56 | CN¥0.76 | CN¥0.71 |
| Revenue Per Share | CN¥7.30 | CN¥8.42 | CN¥8.78 | CN¥8.99 | CN¥9.40 |
| Shares | |||||
| Basic Shares Outstanding | 492.1M | 430.8M | 413.6M | 422.5M | 428.1M |
| Diluted Shares Outstanding | 492.1M | 430.8M | 413.6M | 422.5M | 428.1M |
| Profitability Metrics | |||||
| EBITDA | — | 531.7M | 430.9M | 561.2M | 530.1M |
| D&A | — | 94.4M | 98.8M | 99.3M | 85.8M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026